Introduction
Several integral membrane proteins are now known to be released from the surface of cells through a post-translational proteolytic cleavage event. Examples of proteins existing as both membrane-bound and soluble forms as a result of such proteolytic cleavage include angiotensinconverting enzyme (ACE), the Alzheimer's amyloid precursor protein (APP), the tumour necrosis factor ligand and receptor superfamily, transforming growth factor x , Fas ligand and certain cytokine receptors (reviewed in [l] ). T h e biological function of the proteolytic release of a membrane protein varies. In some cases it might be a process for rapidly down-regulating the protein from the surface of the cell, in others it might be to generate a soluble form of the protein that has properties identical with, or subtly different from, those of the membrane-bound Abbreviations used: ACE, angiotensin-converting enzyme; APP, amyloid precursor protein; fiA4, fi-amyloid peptide; CHO, Chinese hamster ovary; sAPPa, ectodomain of APP released by a-secretase. 'To whom correspondence should be addressed.
form. The cleavage occurs on the extracellular face of the lipid bilayer in the membrane-proximal stalk region of the protein (Figure 1 ). The enzymes responsible for these cleavage events are referred to collectively as secretases, sheddases or convertases, and have many properties in common. For example, they seem to be integral membrane proteins themselves, are zinc metalloproteinases, being sensitive to certain hydroxamic acid-based compounds such as batimastat, and are up-regulated by phorbol esters.
ACE secretase ACE (EC 3.4.15.1) is a type I integral membrane glycoprotein [2, 3] . ACE has a key role in the control of blood pressure and fluid and electrolyte homoeostasis, and inhibitors of the enzyme are used clinically in the treatment of hypertension and congestive heart failure. ACE exists primarily as a membrane-bound protein, although a soluble form is present under normal conditions in blood plasma, amniotic fluid, seminal plasma and other body fluids.
While studying the mode of membrane anchorage of pig kidney ACE, we observed that [lo] suggested that this shift in the position of the secretase cleavage site nearer to the plasma membrane might be due to the N-terminal domain of ACE acting as a conformational inhibitor of the proteolysis by interacting either with the stalk region of ACE or with the secretase itself.
[7-101.
ACE secretase requires its substrate to be membrane-bound
T h e full-length, amphipathic form of ACE was labelled selectively with 3-trifluoromethyl-3-(rn-['251]iodophenyl)diazirine in the membrane-spanning hydrophobic region. Although trypsin was able to cleave the hydrophobic anchoring domain from the bulk of the protein, there was no cleavage of full-length ACE by a Triton X-100-solubilized pig kidney secretase preparation when the substrate was in detergent solution [6] . In contrast, the Triton X-100-solubilized secretase preparation released ACE from pig intestinal microvillar membranes, which lack endogenous secretase activity [S] , and cleaved the purified amphipathic form of ACE when it was incorporated into artificial lipid vesicles. Thus ACE secretase seems to have a requirement for its substrate to be inserted in a lipid bilayer. As ACE secretase could be released from the membrane by trypsin and the solubilized secretase still retained the ability to cleave ACE reconstituted into the lipid vesicles [6], it seems that there is no requirement for the secretase itself to be inserted in a membrane for it to be active. It seems unlikely that this is because of a requirement for a particular cofactor normally present in the membrane, as cleavage still occurred in the reconstituted system when only ACE and phosphatidylcholine were present in the vesicles. More probably this reflects a conformational requirement that exists when ACE is embedded in a membrane but that is absent when the protein is free in solution. One possibility is that in the absence of a lipid bilayer to insert into, the hydrophobic transmembrane domain of ACE binds to other hydrophobic regions on the surface of the same or neighbouring ACE molecules, thereby occluding or altering the conformation of the stalk region and preventing secretase access. T h e observation that ACE secretase has a requirement for its substrate to be inserted in a lipid bilayer might have a significant bearing on the means by which such membrane protein secretases can be assayed and might rule out the use of short soluble synthetic peptides as substitute substrates.
APP a-secretase
Alzheimer's disease is a neurodegenerative disorder characterized by the progressive deposition of the 4 kDa /j-amyloid peptide (/jA4) in extracellular senile plaques. /jA4 is a 40-43-residue polypeptide derived by proteolytic cleavage of the type I integral membrane APP (reviewed in [12, 13] ). Cleavage of APP at the N-terminus of the /jA4 peptide by /j-secretase and at the C-terminus by one or more y-secretases constitutes the amyloidogenic pathway for the processing of APP. In the constitutive nonaniyloidogenic pathway, a-secretase cleaves APP within the PA4 domain between , approx. 12 residues on the luminal side of the transmembrane domain, precluding the formation of the /jA4 peptide. T h e action of a-secretase releases the large ectodomain of APP (sAPPa), which has neuroprotective properties [ 15,161. The identification and characterization of the APP secretases are important for the development of therapeutic strategies to control Volume 27 the build-up of PA4 in the brain and the subsequent pathological effects of Alzheimer's disease.
Although a-secretase has yet to be isolated, this proteinase seems to be plasma membraneassociated [ 17,181, and its activity is up-regulated by phorbol esters and other agents that activate protein kinase C [19, 20] . Roberts et al. [18] described the development of a cell-free assay for r-secretase that used a construct of the C-terminal 105 residues of APP linked to the C-terminus of alkaline phosphatase. Expression of this construct in human H4 neuroglioma cells resulted in cleavage at the prototypic Lys-16-Leu-17 a-secretase cleavage site. Of a range of class-specific proteinase inhibitors examined, only the zinc-chelating agent 1, lo-phenanthroline caused significant inhibition of a-secretase cleavage. With this cell-free assay it was shown that a-secretase could be effectively solubilized with Triton X-100 and CHAPS but not with octyl glucoside, and that a-secretase required the membrane to specifically cleave the substrate. A comparison of the properties of a-secretase and ACE secretase (Table 1 ) led us to propose that these two proteinases are either the same or are closely related integral membrane zinc metalloproteinases [6] .
ACE secretase and a-secretase are inhibited by hydroxamate-based compounds
Following on from our observation that ACE secretase was inhibited by 1,lO-phenanthroline, we examined the effect of a range of hydroxamatebased zinc metalloproteinase inhibitors on its activity [6] . Batimastat (BB94), marimastat (BB2516), BB2116 and TAPI-2 all inhibited ACE secretase with Z,, values in the low micromolar range (Table 2) . Studies with several structurally related compounds indicated that inhibitors with a bulky hydrophobic substitution in the S; position are more potent inhibitors of ACE secretase (compare the potency of batimastat with that of compound l), presumably owing to interaction with a complementary deep binding pocket at the active site, as has been shown for the binding of batimastat to the snake venom metalloproteinase atrolysin C [21] . Compound 4 differs from compound 1 only in the presence of a tertiary amine at its C-terminus; a difference that makes com- As ACE secretase and r-secretase had many properties in common (Table l ) , we examined the effect of a number of the hydroxamate-based compounds on the processing of APP in two neuronal cell lines (SH-SYSY and IMR32) and in human umbilical vein endothelial cells [23] .
Using site-specific antibodies in immunoelectro- phoretic blot analysis of conditioned medium to detect SAPPLY, we found that a-secretase displays a remarkably similar inhibition profile to that observed for ACE secretase (Table 2) , which further highlights the similarities between these two activities.
ACE secretase and a-secretase cleave their substrates at the cell surface
We originally identified ACE secretase in microsoma1 membranes isolated from pig kidney cortex [4] . Subsequently we showed that the secretase was present in purified kidney microvillar membranes [5] . T h e relative lack of contamination of the microvillar membrane preparation by lysosomal, mitochondria1 and endoplasmic reticulum marker enzymes, and the co-enrichment of the secretase with the microvillar membrane markers alkaline phosphatase and ACE, indicated that the secretase was a component of the microvillar membrane. Subsequent pulse-chase and surface-labelling experiments [9, 10, 24] have confirmed that ACE secretase is localized at the plasma membrane. The cellular location of the a-secretase cleavage of APP has been the subject of much debate. There are conflicting data on whether a-secretase cleaves APP at the cell surface, within an intracellular compartment, or at both locations (discussed in [ 12, 25, 26] ). Recently we have exploited our observation that a-secretase is inhibited by hydroxamate-based zinc metalloprotease inhibitors [23] to determine the relative contribution of cell-surface to intracellular a-secretase activity by using a cell-impermeant biotinylated derivative of one such inhibitor (AMG2380) (S. Parvathy, E. H. Karran, A. J. Turner and N. M. Hooper, unpublished work) . When IMR32 cells were grown in the presence of the biotinylated inhibitor (20 pM), negligible sAPPx was detected in the conditioned medium from the cells. In addition, even after incubation of the cells at 2VC, at which temperature proteins that are normally transported to the cell surface accumulate within the transGolgi network [27] , no sAPPa could be detected in the cell lysates. Therefore cx-secretase seems to be cleaving APP almost entirely at the cell surface.
T o reside at the cell surface, ACE secretase and a-secretase are almost certainly themselves trafficked through the secretory pathway. The lack of intracellular sAPPa shows that a-secretase does not cleave APP en route to the cell surface. This therefore raises the question of how x-secretase acts on APP only at the cell surface and not in the secretory pathway? One possibility is that a-secretase and APP are segregated in different subcompartments or membrane microdomains within the secretory pathway [28] and only physically come into contact at the plasma membrane, possibly in response to external stimuli. Alternatively, a-secretase (and, by analogy, ACE secretase) might be synthesized initially as a catalytically inactive proenzyme that is activated only either at the cell surface or in a late compartment of the secretory pathway (e.g. exocytic vesicles). Activation could occur through proteolysis (as with the matrix metalloproteases and the adamalysin tumour necrosis factor a convertase [29] [30] [31] ), by the removal of an associated inhibitor, or on contact with some other membrane or extracellular component.
Conclusion
It is clear that the secretase that cleaves ACE and the Alzheimer's APP a-secretase have a number of properties in common. Whether they are the same or are closely related integral membrane zinc metalloproteinases awaits their isolation and sequencing. It remains to be determined whether a limited number of secretases are responsible for the cleavage and release of all the structurally and functionally unrelated membrane proteins, or whether there is a larger family of integral membrane zinc metalloproteinases, each with its own particular substrate protein. Introduction dominant mutations associated with three loci Alzheimer's disease (AD) is the most common were found that cause early-onset familial AD dementia worldwide. In most of the cases AD [l] . Furthermore, a polymorphism in the apoE occurs sporadically with an increased risk during allele is a major risk factor [2] , which determines aging. However, in some rare cases, autosomal when, not whether, one is predisposed to develop -- 
